Clinical Trials Logo

Clinical Trial Summary

Acute kidney injury (AKI) or renal impairment is an established complication of cardiac surgery occurring with an incidence up to 30%, To date, no agent has conferred renal protection. Considerable interest has developed in the potential for Nacetylcysteine (NAC) to exert a renoprotective effect in patients undergoing cardiac surgery. Due to the beneficial effect of NAC on contrast nephropathy and its reported anti-inflammatory effects.


Clinical Trial Description

Acute kidney injury (AKI), is a well-known complication of cardiac surgery, with an incidence of up to 30% depending on the definition. AKI caused by cardiac surgery is the second most common cause of AKI in the intensive care unit and is a common and serious postoperative complication of cardiac surgery requiring cardiopulmonary bypass (CPB). The pathogenesis of AKI after CPB is multifactorial, and is mostly due to hypo perfusion, reperfusion injury, activation of the systemic inflammatory response, and/or low cardiac output. Reperfusion will result in the formation of reactive oxygen species, resulting in injury to tissues. The activation of the systemic inflammatory response is mostly due to the exposure of blood to the extracorporeal CPB circuit, resulting in the activation of the immune system, which is also mediated by the generation of reactive oxygen species. This results in increased recruitment of neutrophils, macrophages, and lymphocytes into the renal parenchyma, leading to AKI. N-acetylcysteine (NAC) is well known for its antioxidant and free-radical scavenging properties, as well as its vasodilator properties. Its antioxidant properties enable it to prevent ischemic cell death, and as a free-radical scavenger, NAC mitigates the effect of increased reactive oxygen species caused by reperfusion. Hence, theoretically, NAC is able to counteract several mechanisms of kidney injury during cardiac surgery, namely, the systemic inflammatory response, free-radical injury, and ischemia. In this study, we aimed to investigate if the perioperative use of acetylcysteine will prevent kidney injury after cardiac surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05555511
Study type Interventional
Source Ain Shams University
Contact Mohamed A. Alhadidy, MD
Phone 00201005092648
Email Mohamed_alaaeldin@med.asu.edu.eg
Status Recruiting
Phase N/A
Start date August 26, 2022
Completion date February 26, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT05710978 - Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain N/A
Recruiting NCT06125184 - Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock N/A
Completed NCT01824771 - Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients
Recruiting NCT05189262 - Cardiopulmonary Bypass Induced Red Blood Cell Lysis
Completed NCT04921475 - Renal Regional Oxygen Saturation During Transcatheter Aortic Valve Implantation
Withdrawn NCT00306059 - Early Goal Directed Therapy for Acute Kidney Injury Phase 2
Recruiting NCT05426291 - Acute Kidney Damage in Patients Undergoing Open Heart Surgery
Not yet recruiting NCT04181281 - Validation of Renal Perfusion CEUS Against MRI, and Its Application in Acute Kidney Injury
Recruiting NCT02417896 - Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery N/A